Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
Listed Suppliers
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Sulfachloropyridazine Sodium
2. 23282-55-5
3. Sulfachlorpyridazine Sodium
4. Sodium Sulfachlorpyridazine
5. Sodium Sulfachloropyridazine
6. Sulfachlorpyridazine Sodium Salt
7. N1lma4960o
8. Sodium ((4-aminophenyl)sulfonyl)(6-chloropyridazin-3-yl)amide
9. Sodium;(4-aminophenyl)sulfonyl-(6-chloropyridazin-3-yl)azanide
10. Vetisulid
11. Sodium N-(6-chloropyridazin-3-yl)sulphanilamidate
12. Benzenesulfonamide, 4-amino-n-(6-chloro-3-pyridazinyl)-, Sodium Salt (1:1)
13. Sulfachloropyridazinesodium
14. Unii-n1lma4960o
15. Einecs 245-553-0
16. N-(6-chloro-3-pyridazine)-4-aminobenzenesulfonainino Sodium Monohydrate
17. Sodium[(4-aminophenyl)sulfonyl](6-chloropyridazin-3-yl)azanide
18. Sulphachloropyridazine Sodium
19. Schembl203597
20. Dtxsid10945973
21. Sulfanilamide, N1-(6-chloro-3-pyridazinyl)-, Monosodium Salt
22. Sulfachlororpyridazine Sodium
23. Bcp12153
24. Mfcd04117866
25. Akos027340239
26. Benzenesulfonamide, 4-amino-n-(6-chloro-3-pyridazinyl)-, Monosodium Salt
27. As-13676
28. Sulfachlorpyridazine Sodium Salt [mi]
29. H11378
30. Sulfachlorpyridazine Sodium [green Book]
31. 282s555
32. A816655
33. W-107411
34. Q27284398
35. Sodium (4-aminophenylsulfonyl)(6-chloropyridazin-3-yl)amide
36. Sodium (4-aminobenzene-1-sulfonyl)(6-chloropyridazin-3-yl)azanide
| Molecular Weight | 306.70 g/mol |
|---|---|
| Molecular Formula | C10H8ClN4NaO2S |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 3 |
| Exact Mass | 305.9954187 g/mol |
| Monoisotopic Mass | 305.9954187 g/mol |
| Topological Polar Surface Area | 95.3 Ų |
| Heavy Atom Count | 19 |
| Formal Charge | 0 |
| Complexity | 370 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Market Place
ABOUT THIS PAGE
A Sulfachlorpyridazine Sodium manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Sulfachlorpyridazine Sodium, including repackagers and relabelers. The FDA regulates Sulfachlorpyridazine Sodium manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Sulfachlorpyridazine Sodium API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Sulfachlorpyridazine Sodium supplier is an individual or a company that provides Sulfachlorpyridazine Sodium active pharmaceutical ingredient (API) or Sulfachlorpyridazine Sodium finished formulations upon request. The Sulfachlorpyridazine Sodium suppliers may include Sulfachlorpyridazine Sodium API manufacturers, exporters, distributors and traders.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Sulfachlorpyridazine Sodium as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Sulfachlorpyridazine Sodium API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Sulfachlorpyridazine Sodium as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Sulfachlorpyridazine Sodium and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Sulfachlorpyridazine Sodium NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Sulfachlorpyridazine Sodium suppliers with NDC on PharmaCompass.
Sulfachlorpyridazine Sodium Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Sulfachlorpyridazine Sodium GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Sulfachlorpyridazine Sodium GMP manufacturer or Sulfachlorpyridazine Sodium GMP API supplier for your needs.
A Sulfachlorpyridazine Sodium CoA (Certificate of Analysis) is a formal document that attests to Sulfachlorpyridazine Sodium's compliance with Sulfachlorpyridazine Sodium specifications and serves as a tool for batch-level quality control.
Sulfachlorpyridazine Sodium CoA mostly includes findings from lab analyses of a specific batch. For each Sulfachlorpyridazine Sodium CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Sulfachlorpyridazine Sodium may be tested according to a variety of international standards, such as European Pharmacopoeia (Sulfachlorpyridazine Sodium EP), Sulfachlorpyridazine Sodium JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Sulfachlorpyridazine Sodium USP).
LOOKING FOR A SUPPLIER?
